Hosted on MSN1mon
FDA accepts Sentynl’s Menkes disease therapy NDA for priority review
The US Food and Drug Administration (FDA) has accepted for filing and priority review of the new drug application (NDA) for Sentynl Therapeutics' CUTX-101 (copper histidinate) for the treatment of ...
Yahoo Finance20d
Menkes Disease Epidemiology Forecast Research 2020-2034: Increase in Diagnosed Prevalence, Driven by Enhanced Genetic Testing and Awareness
Dublin, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The "Menkes Disease - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. Menkes Disease is an X-linked recessive ...